{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:25:30Z","timestamp":1755998730331,"version":"3.33.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105521","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T07:39:45Z","timestamp":1709019585000},"page":"105521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and comparison of corticosteroids only and corticosteroids with plasmapheresis or intravenous immunoglobulin for the treatment of optic neuritis in demyelinating disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2795-1484","authenticated-orcid":false,"given":"Arnaud","family":"Gaulier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Benoit","family":"Hardouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Wiertlewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lebranchu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105521_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105521_bib0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"23","key":"10.1016\/j.msard.2024.105521_bib0003","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"S0002-9394","author":"Chen","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105521_bib0004","article-title":"Optic neuritis classification in 2021","author":"Ducloyer","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105521_bib0005","first-page":"494","article-title":"Plasmapheresis affects T helper type-1\/T helper type-2 balance of circulating peripheral lymphocytes","volume":"5","author":"Goto","year":"2001","journal-title":"Ther. Apher. Off. J. Int. Soc. Apher. Jpn. Soc. Apher."},{"key":"10.1016\/j.msard.2024.105521_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418774973","article-title":"Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica","volume":"11","author":"Hoffmann","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105521_bib0007","first-page":"685","article-title":"Clinical characteristics, treatment and prognosis of myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in children","volume":"100","author":"Hou","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.msard.2024.105521_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-2094-9-80","article-title":"Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis","volume":"9","author":"Koziolek","year":"2012","journal-title":"J. Neuroinflammat."},{"key":"10.1016\/j.msard.2024.105521_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102325","article-title":"Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)","volume":"44","author":"Li","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105521_bib0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J. Clin. Apheresis"},{"key":"10.1016\/j.msard.2024.105521_bib0011","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105521_bib0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2024.105521_bib0013","first-page":"65","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurol. Barc. Spain"},{"key":"10.1016\/j.msard.2024.105521_bib0014","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2024.105521_bib0015","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"The BMJ"},{"key":"10.1016\/j.msard.2024.105521_bib0016","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis","volume":"64","author":"Roed","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105521_bib0017","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000447059","article-title":"Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption - observational multicenter study with 147 patients","volume":"75","author":"Schimrigk","year":"2016","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.msard.2024.105521_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000504027","article-title":"Visual outcomes of plasma exchange treatment of steroid-refractory optic neuritis: a retrospective monocentric analysis","volume":"46","author":"Skorupka","year":"2019","journal-title":"Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfusionsmedizin Immunhamatologie"},{"key":"10.1016\/j.msard.2024.105521_bib0019","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaneurol.2017.4842","article-title":"Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis","volume":"75","author":"Stork","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2024.105521_bib0020","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1177\/11206721211065218","article-title":"Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: a systematic review and meta-analysis","volume":"32","author":"Zhang","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.msard.2024.105521_bib0021","article-title":"The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann. Palliat. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:40:10Z","timestamp":1738064410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"alternative-id":["S2211034824001007"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105521","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and comparison of corticosteroids only and corticosteroids with plasmapheresis or intravenous immunoglobulin for the treatment of optic neuritis in demyelinating disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105521"}}